Bellevue Life Sciences Acquisition Corp.
10900 NE 4th Street, Suite 2300
Bellevue, WA 98004
VIA EDGAR
February 8, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, DC 20549
Attn: | Ms. Stacie Gorman |
Re: | Bellevue Life Sciences Acquisition Corp. |
Registration Statement on Form S-1
File No. 333-264597
Acceleration Request
|
Requested Date: |
February 9, 2023 | ||
Requested Time: |
4:00 p.m. Eastern Time (or as soon thereafter as practicable) |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Bellevue Life Sciences Acquisition Corp., a Delaware corporation (the Registrant), hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on February 9, 2023 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes K&L Gates LLP, counsel to the Registrant, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to our counsel, K&L Gates LLP, by calling Ms. Julie Rizzo at (919) 743-7336.
* * *
[Signature Page Follows]
Sincerely, | ||
Bellevue Life Sciences Acquisition Corp. | ||
By: | /s/ Kuk Hyoun Hwang | |
Kuk Hyoun Hwang | ||
Chief Executive Officer |
cc: | Gary Kocher, K&L Gates LLP |
Julie Rizzo, K&L Gates LLP